{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:19:24Z","timestamp":1777637964625,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.msard.2022.104081","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T03:24:28Z","timestamp":1659151468000},"page":"104081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8665-4889","authenticated-orcid":false,"given":"Julie","family":"Ravn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik Boye","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preben Borring","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika Katarzyna","family":"G\u00f3ra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-2188","authenticated-orcid":false,"given":"Tobias","family":"Sejbaek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2022.104081_bib0001","first-page":"103","article-title":"[Treatment of psoriasis vulgaris]","volume":"13","author":"Schweckendiek","year":"1959","journal-title":"Med. Monatsschr."},{"issue":"1","key":"10.1016\/j.msard.2022.104081_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molmed.2004.11.003","article-title":"Dimethyl fumarate for psoriasis: more than a dietary curiosity","volume":"11","author":"Mrowietz","year":"2005","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.msard.2022.104081_bib0003","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.14947","article-title":"Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm(R) - and placebo-controlled trial (BRIDGE)","volume":"176","author":"Mrowietz","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.msard.2022.104081_bib0004","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-Controlled Phase 3 Study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2022.104081_bib0005","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-Controlled Phase 3 Study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104081_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.msard.2022.104081_bib0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/nmt-2020-0025","article-title":"Diroximel fumarate in the treatment of multiple sclerosis","volume":"10","author":"Jonasson","year":"2020","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2022.104081_bib0008","article-title":"Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 Study","author":"Naismith","year":"2019","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.104081_bib0009","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, Phase III EVOLVE-MS-2 Study","volume":"34","author":"Naismith","year":"2020","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.msard.2022.104081_bib0010","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1007\/s12325-019-01085-3","article-title":"Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study","volume":"36","author":"Palte","year":"2019","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.msard.2022.104081_bib0011","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-021-00799-9","article-title":"Pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam\u2122 (monomethyl fumarate) or Tecfidera(\u00ae) (dimethyl fumarate)","volume":"35","author":"Lategan","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2022.104081_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102335","article-title":"Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate","volume":"45","author":"Wynn","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2022.104081_bib0013","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00415-017-8509-9","article-title":"Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases","volume":"264","author":"Gieselbach","year":"2017","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.104081_bib0014","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1177\/1352458519852100","article-title":"A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence","volume":"25","author":"Diebold","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.104081_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2019.01.007","article-title":"Factors associated with dimethyl fumarate-induced lymphopenia","volume":"398","author":"Sainz de la Maza","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2022.104081_bib0016","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00415-021-10412-0","article-title":"Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis","volume":"268","author":"Lucchini","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104081_bib0017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Sierra Morales","year":"2020","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104081_bib0018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2022.104081_bib0019","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"2","key":"10.1016\/j.msard.2022.104081_bib0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104081_bib0021","doi-asserted-by":"crossref","first-page":"e01921","DOI":"10.1002\/brb3.1921","article-title":"The Danish Multiple Sclerosis Registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.msard.2022.104081_bib0023","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2017.12.003","article-title":"Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count","volume":"20","author":"Baharnoori","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104081_bib0024","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2022.104081_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing\u2013remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.104081_bib0026","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/1352458514559299","article-title":"Dimethyl fumarate associated lymphopenia in clinical practice","volume":"21","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"10","key":"10.1016\/j.msard.2022.104081_bib0027","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40263-018-0543-3","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, Multicenter, Real-World Study","volume":"32","author":"Mirabella","year":"2018","journal-title":"CNS Drugs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:14Z","timestamp":1761901514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":26,"alternative-id":["S2211034822005892"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104081","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104081"}}